First Trust NYSE Arca Biotechnology Index Fund
253 hedge funds and large institutions have $546M invested in First Trust NYSE Arca Biotechnology Index Fund in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 86 reducing their positions, and 20 closing their positions.
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
1% more funds holding
Funds holding: 250 → 253 (+3)
0.68% less ownership
Funds ownership: 50.59% → 49.91% (-0.68%)
13% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 86
29% less capital inflows, than outflows
Capital inflows: $25.4M | Capital outflows: $35.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.48M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3M |
| 3 |
NA
Navellier & Associates
Reno,
Nevada
|
+$1.99M |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$1.26M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$8.74M |
| 2 |
Ameritas Advisory Services
Lincoln,
Nebraska
|
-$6.17M |
| 3 |
YC
Yarbrough Capital
Franklin,
Tennessee
|
-$5.03M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.59M |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$1.25M |
FBT Hedge Fund Activity: Q3 2025 in Review
253 of the 7,647 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q3 2025, worth a combined $546M — up 7.1% from $510M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new FBT positions and 20 closed out — a net gain of 6 holders — while 75 added to existing stakes and 86 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $3.48M. The largest seller was Goldman Sachs, cutting an estimated $8.74M.
- 253 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q3 2025, up from 250 in Q2 2025.
- Funds reported $546M of First Trust NYSE Arca Biotechnology Index Fund stock for Q3 2025, up 7.1% quarter-over-quarter.
- 26 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q3 2025 and 20 closed out, a net change of +6 holders.
- The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q3 2025 was Citadel Advisors, an estimated $3.48M added.
- The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q3 2025 was Goldman Sachs, an estimated $8.74M sold.
Based on aggregated 13F filings for Q3 2025.